Health & Life Sciences

Overview

As a stakeholder in the health and life sciences industry, you work every day to extend the boundaries of human health and enhance patient care. Our national health and life sciences industry team partners with you to advance your objectives in a complex and heavily regulated environment. Whether collaborating with a pharmaceutical company to guide a new drug through the product development life cycle or helping health care providers implement compliance programs, we provide business-minded strategies and legal solutions to navigate your most pressing challenges. We have completed major health care transactions, represented health providers in high-stakes litigation, and executed public policy and government affairs strategies for research institutions and patient advocacy organizations. Our professionals have served as in-house counsel for health systems and global pharmaceutical and device companies, health policy specialists at the congressional and agency level, and counsel at the Department of Justice (DOJ) and the Food and Drug Administration (FDA).

Health & Life Sciences

Overview

Libby Baney Discusses Opioid Epidemic and Internet Regulation with National Journal

Sunlight Shown to Be an Effective Disinfectant Against Domain Name Abuse

Patient Perspectives—There’s an App for That!

Patient Perspectives—There’s an App for That!

New FTC Guidance Will Require HSR Filings for More Nonprofit Hospital Affiliations/Combinations

The Election’s Impact on Health Care Interests

Settlement Counsel: The Key Driver to Resolving a Mass Tort More Efficiently

The Role of the Virtual Law Team in Defending Litigation of All Sizes

3 Areas of Renewed Interest for Biotechnology, Chemical and Pharmaceutical Patents

Patient Perspectives—There’s an App for That!

The Election’s Impact on Health Care Interests

Trick or Treat? Expected and Surprising Provisions in the New Medicare Advantage Regulation

Biologic and Biosimilar Settlement Agreements Now Must Be Disclosed to DOJ and FTC

Requiring a Price Tag in Drug Commercials: Furthering Consumer Transparency or Government Overreach?

Beware Billing Medicare for Non-Approved Imported Drugs

Patient Perspectives—There’s an App for That!

CRISPR Technology: Broad Institute of MIT and Harvard Wins Pivotal Patent Battle on Appeal

Tricia Beckmann Shares Comments About Health Care Enrollment With Inside Health Policy

Insights & Events

Joe Price Featured in Finance and Commerce

Mike Adelberg Discusses Errors in MA Plans with The Washington Post

Association Health Plan Final Rule Brings New Coverage Options for Small Businesses and Self-Employed

Related Services and Industries

Experience

Our Experience